




FOUR RECEPTORS. ONE CONJUGATE.

Multi-targeted protein–drug conjugates for
glioblastoma and difficult-to-treat cancers

Next-Generation Targeted Oncology Platforms

**Multi-targeted protein–drug conjugates,
blood–brain barrier delivery and theranostic
radioligands for difficult-to-treat cancers**

WPD401

Multi-targeted PDC

BBB platform


IL-13R α 2 biologic

WPD103

Theranostic radioligand

WPD401 is designed to address tumor heterogeneity

A single protein-drug conjugate engages four tumor-associated receptors and carries the DM1 payload.



The problem

Single-target therapies can leave receptor-negative or low-expression tumor subpopulations insufficiently covered.

The design


Engineered IL-13 targets IL-13Rα2; an ephrin-derived domain targets EphA2, EphA3 and EphB2; lysine-directed conjugation attaches DM1.

IP protection

Ilcensed and proprietary assets | WPD-led program development | platform optionality across payloads and indications.

Canine glioma studies provide a translational foundation for CED

Spontaneous canine gliomas are immunocompetent and share clinically relevant features with human GBM.



12 mo Post-Rx-SD

12-month post-treatment MRI

94%

of treated dogs showed
tumor-size reduction

Published CED study

50%

objective response rate
reported

Published CED study


up to 95%

tumor reduction in
related receptor-targeted
CED agents

Related receptor-targeted programs

What the studies support

A practical local-delivery precedent, evidence of target engagement in an immunocompetent spontaneous tumor model, and a basis for safety and procedure planning.




Clinical entry through recurrent glioblastoma

A planned Phase I study is designed to establish safety, feasibility, dose selection and preliminary proof of concept.

PLANNED PHASE I DESIGN

- **Population:** patients with recurrent GBM
- **Design:** single-center, open-label dose escalation
- **Administration:** direct intratumoral CED
- **Primary objectives:** safety, tolerability and recommended dose
- **Secondary objectives:** preliminary efficacy, PFS6, overall survival, biomarkers and feasibility
- **Leadership:** Wake Forest University with WPD as technology owner and development partner



Why local CED first?

Direct delivery is intended to bypass limited BBB penetration, reduce systemic exposure and lower cost and initial product requirements — while preserving the need to demonstrate procedural feasibility and local CNS safety.



The same receptor set supports a portfolio beyond glioblastoma

Recurrent GBM is the lead indication; receptor biology also supports expansion into selected brain metastases and TNBC.

Indication	IL-13R α 2	EphA2	EphA3	EphB2
Glioblastoma	High	High	High	High / moderate
Triple-negative breast cancer	High / moderate	High	High / moderate	High / moderate
Lung cancer brain metastases	High / moderate	High	High / moderate	High / moderate
Melanoma brain metastases	Moderate	High	High / moderate	Moderate
Pancreatic / colorectal cancer	High	High	Moderate	Variable

High
High / moderate
Moderate
Variable
Limited

Initial market

Recurrent glioblastoma
High unmet need
Limited effective therapies
Local CED enables direct tumor exposure

Why WPD401 can differentiate

4 targets: IL-13Ra2 + EphA2 + EphA3 + EphB2
Designed for heterogeneous tumors
Local delivery bypasses the BBB challenge


Expansion potential

Newly diagnosed GBM
Brain metastases
Other way of delivery
TNBC and other receptor-positive tumors

EUR10M to take WPD401 from IND-enabling development to phase II

CAPITAL PLAN

Three financing tranches link capital deployment to scientific, regulatory and partnering milestones.



Experienced leadership across science, clinical development, quality and execution

Partner with WPD to advance WPD401 toward human proof of concept and unlock the broader platform.



Mariusz Olejniczak, PhD
CEO / Co-founder



Marek Sipowicz, MD, PhD
Chief Medical Officer



**Beata Pajak-Tarnacka,
Prof., EMBA**
Chief Scientific Officer

**Seeking EUR 2 - 4 M
strategic partners**

Purpose: Advance WPD401 through IND and Phase I clinical proof-of-concept

Key milestone: First-in-human validation in recurrent GBM

Strategic objective: Out-licensing or co-development in ADC / CNS oncology

**Partner
with WPD**

Advance WPD401 toward first-in-human proof of concept while building options in systemic BBB delivery, theranostics and additional solid tumors.

mariusz.olejniczak@wpdpharmaceuticals.com
+48 515 262 381